By Katherine Hamilton
Simulations Plus posted a lower profit for its first fiscal quarter of 2025 as the cost of its software and services rose.
The company, which provides modeling and simulation software to biopharmaceutical companies, posted a profit of $206,000, or 1 cent a share, in the three months ended Nov. 30, compared with $2 million, or 10 cents a share, a year earlier.
Stripping out certain one-time items, adjusted per-share earnings were 17 cents, in line with what FactSet analysts expected.
Revenue rose 31% to $18.9 million. Analysts surveyed by FactSet forecast revenue of $18.8 million.
Simulations Plus reiterated its 2025 guidance of $90 million to $93 million in revenue.
Costs of revenues for software and services roughly doubled year-over-year. Services revenue increased 19%, but faced some challenges because client-driven data was postponed, the company said.
"Overall, our team achieved solid results despite ongoing funding challenges and cost constraints in the pharma and biotech sectors," said chief executive Shawn O'Connor.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
January 07, 2025 16:36 ET (21:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。